Price T Rowe Associates Inc Deciphera Pharmaceuticals, Inc. Transaction History

Price T Rowe Associates Inc

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$13.58 - $17.36 $26,942 - $34,442	1,984 Added 14.84%	15,355 $242,000
Q4 2023 Feb 14, 2024	BUY	$10.11 - $16.54 $16,418 - $26,860	1,624 Added 13.82%	13,371 $216,000
Q3 2023 Nov 14, 2023	BUY	$12.46 - $15.48 $17,618 - $21,888	1,414 Added 13.68%	11,747 $150,000
Q2 2023 Aug 14, 2023	SELL	$13.28 - $15.96 $7.83 Million - $9.41 Million	-589,342 Reduced 98.28%	10,333 $146,000
Q1 2023 May 15, 2023	SELL	$14.26 - $22.1 $359,523 - $557,185	-25,212 Reduced 4.03%	599,675 $9.27 Million
Q4 2022 Feb 14, 2023	SELL	$14.85 - $19.04 $1.36 Million - $1.75 Million	-91,870 Reduced 12.82%	624,887 $10.2 Million
Q3 2022 Nov 14, 2022	BUY	$12.38 - $20.23 $7.06 Million - $11.5 Million	569,958 Added 388.26%	716,757 $13.3 Million
Q2 2022 Aug 15, 2022	BUY	$9.11 - $13.98 $1.34 Million - $2.05 Million	146,799 New	146,799 $1.93 Million
Q1 2022 May 16, 2022	SELL	$6.87 - $11.11 $2.14 Million - $3.46 Million	-311,669 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$7.7 - $37.13 $1.06 Million - $5.1 Million	-137,430 Reduced 30.6%	311,669 $3.05 Million
Q3 2021 Nov 15, 2021	SELL	$26.46 - $37.15 $1.86 Million - $2.61 Million	-70,177 Reduced 13.51%	449,099 $15.3 Million
Q2 2021 Aug 16, 2021	SELL	$32.73 - $47.95 $21.2 Million - $31.1 Million	-648,992 Reduced 55.55%	519,276 $19 Million
Q1 2021 May 17, 2021	SELL	$40.39 - $56.73 $267,543 - $375,779	-6,624 Reduced 0.56%	1,168,268 $52.4 Million
Q4 2020 Feb 16, 2021	BUY	$51.77 - $66.18 $60.8 Million - $77.8 Million	1,174,892 New	1,174,892 $67.1 Million

343K

500

Ticker DCPH
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 66,822,100
Description
Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gas...

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

Stay updated on Price T Rowe Associates Inc with notifications on news.